Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


Sergey Suchkov

Sergey Suchkov

I M Sechenov First Moscow State Medical University, Russia

Title: Proteolytic abzymes as translational tools of the newest generation to be exploited for bi-odesign and bioengineering


Biography: Sergey Suchkov


Catalytic Abs (catAbs) are multivalent immunoglobulins (Igs) with a capacity to hydrolyze the antigenic (Ag) substrate. In this sense, proteolytic Abs (Ab-proteases) represents Abs to provide proteolytic effects. Abs against myelin basic protein/MBP with proteolytic activity exhibiting sequence-specific cleavage of MBP is of great value to monitor demyelination whilst in multiple sclerosis. The activity of Ab-proteases was first registered at the subclinical stages, 1-2 years prior to the clinical illness and the activity of the Ab-proteases revealed significant correlation with scales of demyelination and the disability of the patients as well. So, the activity of Ab-proteases and its dynamics tested would confirm a high subclinical and predictive (translational) value of the tools as applicable for personalized monitoring protocols. Ab-proteases directly affecting remodeling of tissues with multilevel architectonics (for instance, myelin) are of tremendous value. By changing sequence specificity one may reach reduction of a density of the negative proteolytic effects within the myelin sheath and thus minimizing scales of demyelination. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism or could be designed for the development of new catalysts with no natural counterparts. Further studies are needed to secure artificial or edited Ab-proteases as translational tools of the newest generation to diagnose, to monitor, to control and to treat and rehabilitate multiple sclerosis patients at clinical stages and to prevent the disorder at subclinical stages in persons at risks.


  1. Gabibov A A, Paltsev M A and Suchkov S V (2011) Antibody-associated proteolysis in surveillance of autoimmune demyelination: clinical and preclinical issues. Future Neurology 6(3):303-305.
  2. D Kostyushev, I Tsarev, D Gnatenko, M Paltsev and S Suchkov (2011) Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression. Open J Immunology 1(3):80-86.
  3. Gabibov A G, Ponomarenko N A, Tretyak E B, Paltsev M A and Suchkov S V (2006) Catalytic autoantibodies in clinical autoimmunity and modern medicine. Autoimmunity Reviews 2006(5):324-330.
  4. Ponomarenko N A, Durova O M, Vorobiev I I, Belogurov A A, Telegin G B, et al. (2005) Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol. Lett. 103(1):45-50.
  5. Ponomarenko N A, Durova O M, Vorobiev I I, Aleksandrova E S, Telegin G B, et al. (2002) Catalytic antibodies in clinical and experimental pathology: human and mouse models. Journal of Immunological Methods 2002(269):197-211.